Genomic Testing and the Evolving Role of PARP Inhibitors in Prostate Cancer - Tanya Dorff
Tanya Dorff
Neeraj Agarwal and Tanya Dorff discuss the evolving role of genomic testing and PARP inhibitors in prostate cancer, with a focus on patient selection and treatment decision-making.
A Real-World Study of mHSPC Patients: Comparative Survival with Apalutamide and Enzalutamide - Neal Shore
Neal Shore
Neeraj Agarwal speaks with Neal Shore about a real-world analysis comparing overall survival in patients with metastatic hormone-sensitive prostate cancer treated with apalutamide versus enzalutamide.
